Adoptive T-cell therapy using EMPD-specific chimeric antigen receptors for treating IgE-mediated allergic diseases
US11384156B2 · kind B2 · utility
1Cited by
4References
26Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Jul 17, 2017 |
| Grant date | Jul 12, 2022 |
| Priority date | — |
| Expiry date | Jul 17, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2800/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A chimeric antigen receptor specific for the extracellular membrane-proximal domain (EMPD) of membrane-bound IgE (mIgE) is provided. The EMPD-specific chimeric antigen receptor comprises an extracellular ligand binding domain capable of binding EMPD, a transmembrane domain, and an intracellular domain that mediates T cell activation upon EMPD binding. Nucleic acids and vectors encoding the EMPD-specific chimeric antigen receptor are provided. T cells transduced with such vectors find use in chimeric antigen receptor-based adoptive T-cell therapy for targeting IgE-expressing B cells and treating IgE-mediated allergic diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.